This trial is active not recruiting!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Chronic Lymphocytic Leukemia
and you are
over 65
years old
This is an observational trial.
You are contributing to medical knowledge about your condition.
Show me locations

The purpose

The planned analysis is a prospective cost-effectiveness (cost-utility) analysis from the perspective of the Canadian public healthcare system, examining the costs and outcomes (quality-adjusted life years gained) of ibrutinib-based therapy compared to a standard therapy (bendamutine-rituximab). Collection and management of the data required for the economic analyses (including resource utilization and outcomes) will be fully integrated into the clinical data. Health state utilities will be derived directly from the study population.
Tris trial is registered with FDA with number: NCT02414022. The sponsor of the trial is Canadian Cancer Trials Group and it is looking for 51 volunteers for the current phase.
Official trial title:
A Prospective Economic Analysis NCIC CTG CLC.2/ALLIANCE A041202: A Randomized Phase III CLL Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (≥65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)